AIM ImmunoTech Inc. (NYSE:AIM) CEO Purchases $25,308.89 in Stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels bought 61,729 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The shares were acquired at an average cost of $0.41 per share, for a total transaction of $25,308.89. Following the completion of the purchase, the chief executive officer now owns 778,184 shares in the company, valued at $319,055.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

AIM ImmunoTech Trading Down 1.2 %

Shares of NYSE:AIM opened at $0.42 on Friday. AIM ImmunoTech Inc. has a 52 week low of $0.32 and a 52 week high of $0.75. The company’s 50 day moving average is $0.43 and its two-hundred day moving average is $0.44. The company has a market cap of $21.32 million, a PE ratio of -0.70 and a beta of -0.11.

AIM ImmunoTech (NYSE:AIM) last issued its earnings results on Friday, March 29th. The company reported ($0.26) EPS for the quarter. AIM ImmunoTech had a negative return on equity of 121.69% and a negative net margin of 14,337.62%. The firm had revenue of $0.07 million for the quarter.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).